Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections

US10035809B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10035809-B2
Application numberUS-201715599151-A
CountryUS
Kind codeB2
Filing dateMay 18, 2017
Priority dateDec 21, 2012
Publication dateJul 31, 2018
Grant dateJul 31, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R 1 , X, W, Y 1 , Y 2 , Z 1 , and Z 4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound having Formula (I): or a stereoisomer or pharmaceutically acceptable salt thereof, wherein: X is —NZ 3 —; W is —CHZ 2 —; Z 2 is hydrogen; Z 1 and Z 3 , taken together, form -L-, wherein L is —C(R a ) 2 —; Z 4 is —CH 2 CH 2 —; Y 1 and Y 2 are each independently hydrogen, C 1-3 alkyl or C 1-3 haloalkyl; R 1 is phenyl substituted with one, two or three halogens; and each R a is, independently, hydrogen, halogen, hydroxy or C 1-4 alkyl. 2. The compound of claim 1 , wherein the compound is selected from the group consisting of: 3. A pharmaceutical composition comprising a compound of claim 1 , or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

Assignees

Inventors

Classifications

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • for HIV · CPC title

  • Antivirals · CPC title

  • C07D471/18Primary

    Bridged systems · CPC title

  • spiro-condensed or forming part of bridged ring systems · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10035809B2 cover?
Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R 1 , X, W, Y 1 , Y 2 , Z 1 , and Z 4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceuti…
Who is the assignee on this patent?
Gilead Sciences Inc
What technology area does this patent fall under?
Primary CPC classification C07D471/18. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).